OncBioMune Acquires Propolis Product Line For German Partner
BATON ROUGE, LA--(Marketwired - July 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce the acquisition of the rights to six Aagaard® Propolis products for the Mexican markets from the Company's German partner roha Arzneimittel GmbH ("roha"). OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.
OncBioMune has acquired from roha the Mexican rights to:
•Aagaard® Propolis Syrup
•Aagaard® Propolis Kids Lozenges
•Aagaard® Propolis Adult Lozenges
•Aagaard® Propolis Capsules
•Aagaard® Propolis Chewable Lozenges
•Aagaard® Propolis Royal Jelly and Vitamin C Capsules
Propolis, sometimes referred to as "bee glue," is a product rich in polyphenols called flavonoids produced by honey bees. Two main immunopotent chemicals in propolis have been identified as caffeic acid phenethyl ester (CAPE) and artepillin C, chemicals known to have a wide array of positive effects related to immunosuppression, macrophage function and more. More broadly, although scientific research is limited, propolis is believed to have antibacterial, antiviral, antifungal, and anti-inflammatory properties. The combination of benefits, along with strong bioavailability and a good historical safety profile, have resulted in propolis serving as the active ingredient in traditional medicines for thousands and years and in over-the-counter medical products sold globally today.
"roha sources only the best propolis from all over the world in creating their Aagaard® line. As a result, it is the number one seller of propolis-based products in Europe," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "We believe that we can have the products in from roha's state-of-the-art manufacturing facility and on shelves in Mexico for the flu season, which should provide a nice kick-start to our sales efforts that we estimate should generate approximately $300,000 in gross revenue annually." Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.